BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more
BioNTech SE (BNTX) - Total Assets
Latest total assets as of September 2025: $21.34 Billion USD
Based on the latest financial reports, BioNTech SE (BNTX) holds total assets worth $21.34 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioNTech SE - Total Assets Trend (2016–2024)
This chart illustrates how BioNTech SE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioNTech SE - Asset Composition Analysis
Current Asset Composition (December 2024)
BioNTech SE's total assets of $21.34 Billion consist of 83.5% current assets and 16.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.3% |
| Accounts Receivable | $1.52 Billion | 6.8% |
| Inventory | $283.30 Million | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $790.40 Million | 3.5% |
| Goodwill | $380.60 Million | 1.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how BioNTech SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioNTech SE's current assets represent 83.5% of total assets in 2024, an increase from 81.6% in 2016.
- Cash Position: Cash and equivalents constituted 43.3% of total assets in 2024, down from 77.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.8% of total assets.
BioNTech SE Competitors by Total Assets
Key competitors of BioNTech SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BioNTech SE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioNTech SE generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioNTech SE is currently not profitable relative to its asset base.
BioNTech SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.12 | 7.33 | 2.75 |
| Quick Ratio | 7.02 | 7.21 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.61 Billion | $ 15.96 Billion | $ 1.06 Billion |
BioNTech SE - Advanced Valuation Insights
This section examines the relationship between BioNTech SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.23 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | $22.53 Billion |
| Market Capitalization | $9.48 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BioNTech SE's assets below their book value (0.42 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: BioNTech SE's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BioNTech SE (2016–2024)
The table below shows the annual total assets of BioNTech SE from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $22.53 Billion | -2.07% |
| 2023-12-31 | $23.01 Billion | -1.17% |
| 2022-12-31 | $23.28 Billion | +47.05% |
| 2021-12-31 | $15.83 Billion | +582.77% |
| 2020-12-31 | $2.32 Billion | +190.68% |
| 2019-12-31 | $797.65 Million | +22.15% |
| 2018-12-31 | $652.99 Million | +74.26% |
| 2017-12-31 | $374.71 Million | -3.91% |
| 2016-12-31 | $389.96 Million | -- |